[View original text]

On 20th of August, AIDOT (CEO Jeong Jae-hoon), an artificial intelligence (AI)-based medical company announced that it has completed attracting 3 billion won in Series A investment from Korea Investment & Securities and Fine Value Asset Management.

Through this attraction, AIDOT is equipped with a booster to speed up the current domestic and overseas medical device certification and export.

Since its foundation in June 2014, it has been recognized for its technology by selecting a childcare company at the Incheon Creative Economy Innovation Center and selecting 

various government projects such as KIC China. It has developed and commercialized the world's first cervical cancer artificial intelligence diagnostic system "Cerviray" and 

pre-stroke carotid artery diagnostic system "SONO dot AI". In addition, artificial intelligence diagnostic systems in all fields of digestive organ are also in the final stages of 

development.

In addition, it was selected as a empirical special case operator by the Health Insurance Review and Assessment Service and a special regulatory zone operator in Gangwon-do, 

respectively, and is aiming for the global market by developing an AI system for ureteral stones and an AI advance diagnosis system for liver diseases.

All of the products developed and completed by AIDOT so far have been successfully completed through government R&D projects. Attracting this investment is like having a booster attached to commercialization for global export. In particular, Cerviray System is making additional advances into the Indonesian market through exclusive contracts with large 

domestic companies.

In addition, AIDOT explained that requests for cooperation are flooding not only in Southeast Asia, but also from Russian and Indian companies.

PIC in AIDOT said, “I am happy to be able to aggressively proceed with exports through this investment, which have been delayed due to lack of marketing funds for overseas 

expansion.” You will soon be able to see what they are doing. Through this investment attraction, we will complete our position as a global company based on solid export 

performance.”

Also, AIDOT CEO Jae-hoon Jeong said, "I think this series A's successful investment attraction has completed additional objective verification of AIDOT's business feasibility and 

technology. As Silicon Valley investment institutions are also sending love calls, they will closely cooperate with investors in this round to consider attracting additional overseas 

investment, and will not only push for a listing on the domestic KOSDAQ based on sales performance but also consider overseas listing. As AIDOT is a company that has researched and grown with taxpayers' prrecious money, we will grow into a company that sets the right example for the development of the domestic medical artificial intelligence industry."

20th. Aug. 2021. / Artificial Intelligence Newspaper / Reporter Mi-joon Jeon